Exagen (NASDAQ:XGN) Given New $10.00 Price Target at TD Cowen

Exagen (NASDAQ:XGN) had its price target reduced by analysts at TD Cowen from $13.00 to $10.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. TD Cowen’s target price points to a potential upside of 164.06% from the company’s current price.

Other analysts have also recently issued research reports about the stock. BTIG Research cut their price objective on shares of Exagen from $15.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday, February 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Exagen in a research report on Wednesday, January 21st. B. Riley Financial reiterated a “buy” rating and set a $8.00 price target (down from $18.00) on shares of Exagen in a research report on Friday, January 30th. Finally, Canaccord Genuity Group boosted their price objective on shares of Exagen from $11.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, October 27th. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Exagen presently has an average rating of “Moderate Buy” and an average price target of $11.43.

Exagen Price Performance

NASDAQ:XGN traded up $0.09 during trading hours on Tuesday, hitting $3.79. 232,875 shares of the stock were exchanged, compared to its average volume of 569,213. The company has a current ratio of 4.08, a quick ratio of 4.08 and a debt-to-equity ratio of 1.35. The firm’s fifty day moving average price is $4.86 and its 200 day moving average price is $8.01. The company has a market cap of $85.81 million, a P/E ratio of -4.12 and a beta of 1.90. Exagen has a 52-week low of $2.67 and a 52-week high of $12.23.

Institutional Investors Weigh In On Exagen

Several institutional investors and hedge funds have recently bought and sold shares of the business. Bridgeway Capital Management LLC boosted its position in Exagen by 10.3% in the second quarter. Bridgeway Capital Management LLC now owns 27,800 shares of the company’s stock valued at $194,000 after buying an additional 2,600 shares in the last quarter. Calamos Advisors LLC raised its stake in shares of Exagen by 3.5% during the third quarter. Calamos Advisors LLC now owns 78,090 shares of the company’s stock worth $858,000 after buying an additional 2,677 shares during the last quarter. Truvestments Capital LLC boosted its position in shares of Exagen by 109.5% in the 4th quarter. Truvestments Capital LLC now owns 6,169 shares of the company’s stock worth $38,000 after purchasing an additional 3,225 shares during the last quarter. State Street Corp grew its position in shares of Exagen by 6.9% during the 4th quarter. State Street Corp now owns 71,256 shares of the company’s stock worth $433,000 after buying an additional 4,600 shares during the period. Finally, Huntleigh Advisors Inc. raised its holdings in Exagen by 6.3% in the third quarter. Huntleigh Advisors Inc. now owns 93,353 shares of the company’s stock worth $1,026,000 after purchasing an additional 5,492 shares during the period. Institutional investors own 75.25% of the company’s stock.

About Exagen

Exagen Inc is a molecular diagnostics company focused on improving the detection and management of autoimmune diseases. Headquartered in the United States, the company develops, manufactures and markets laboratory tests designed to help clinicians address diagnostic challenges associated with complex connective tissue disorders.

The company’s flagship product portfolio, marketed under the Avise® brand, includes multi-analyte assays such as the Avise® Connective Tissue Disease (CTD) panel, Avise® Lupus panel and Avise® Sjögren’s panel.